These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 9040502)

  • 1. Physostigmine reversal of scopolamine-induced hypofrontality.
    Prohovnik I; Arnold SE; Smith G; Lucas LR
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):220-8. PubMed ID: 9040502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scopolamine reduces frontal cortex perfusion.
    Honer WG; Prohovnik I; Smith G; Lucas LR
    J Cereb Blood Flow Metab; 1988 Oct; 8(5):635-41. PubMed ID: 3417793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscarinic and nicotinic contributions to cognitive function and cortical blood flow.
    Gitelman DR; Prohovnik I
    Neurobiol Aging; 1992; 13(2):313-8. PubMed ID: 1522945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic versus nicotinic modulation of a visual task. a pet study using drug probes.
    Mentis MJ; Sunderland T; Lai J; Connolly C; Krasuski J; Levine B; Friz J; Sobti S; Schapiro M; Rapoport SI
    Neuropsychopharmacology; 2001 Oct; 25(4):555-64. PubMed ID: 11557169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memory modulation with peripherally acting cholinergic drugs.
    Rush DK; Streit K
    Psychopharmacology (Berl); 1992; 106(3):375-82. PubMed ID: 1570386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical role of CA1 muscarinic receptors on memory acquisition deficit induced by total (TSD) and REM sleep deprivation (RSD).
    Javad-Moosavi BZ; Vaezi G; Nasehi M; Haeri-Rouhani SA; Zarrindast MR
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):128-135. PubMed ID: 28571775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional activation of cerebral blood flow abolished by scopolamine is reversed by cognitive enhancers associated with cholinesterase inhibition: a positron emission tomography study in unanesthetized monkeys.
    Tsukada H; Kakiuchi T; Ando I; Ouchi Y
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1408-14. PubMed ID: 9190877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinergic agents and delay-dependent performance in the rat.
    Buxton A; Callan OA; Blatt EJ; Wong EH; Fontana DJ
    Pharmacol Biochem Behav; 1994 Dec; 49(4):1067-73. PubMed ID: 7886077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memory-modulatory effects of centrally acting noradrenergic drugs: possible involvement of brain cholinergic mechanisms.
    Introini-Collison IB; Baratti CM
    Behav Neural Biol; 1992 May; 57(3):248-55. PubMed ID: 1319706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinergic modulation of spatial learning in mice in a Morris-type water maze.
    Lamberty Y; Gower AJ
    Arch Int Pharmacodyn Ther; 1991; 309():5-19. PubMed ID: 1888229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of central angiotensin converting enzyme ameliorates scopolamine induced memory impairment in mice: role of cholinergic neurotransmission, cerebral blood flow and brain energy metabolism.
    Tota S; Nath C; Najmi AK; Shukla R; Hanif K
    Behav Brain Res; 2012 Jun; 232(1):66-76. PubMed ID: 22460064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinergic treatment of an amnestic man with a basal forebrain lesion: theoretical implications.
    Chatterjee A; Morris MK; Bowers D; Williamson DJ; Doty L; Heilman KM
    J Neurol Neurosurg Psychiatry; 1993 Dec; 56(12):1282-9. PubMed ID: 8270928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of cerebral blood flow response to somatosensory stimulation through the cholinergic system: a positron emission tomography study in unanesthetized monkeys.
    Tsukada H; Kakiuchi T; Ando I; Shizuno H; Nakanishi S; Ouchi Y
    Brain Res; 1997 Feb; 749(1):10-7. PubMed ID: 9070622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebral blood flow patterns underlying the differential impairment in category vs letter fluency in Alzheimer's disease.
    Keilp JG; Gorlyn M; Alexander GE; Stern Y; Prohovnik I
    Neuropsychologia; 1999 Oct; 37(11):1251-61. PubMed ID: 10530725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release.
    Janowsky DS; Risch SC; Kennedy B; Ziegler M; Huey L
    Psychopharmacology (Berl); 1986; 89(2):150-4. PubMed ID: 3088629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between scopolamine and muscarinic cholinergic agonists or cholinesterase inhibitors on spatial alternation performance in rats.
    Shannon HE; Bemis KG; Hendrix JC; Ward JS
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1071-7. PubMed ID: 2262893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mecamylamine reverses physostigmine-induced attenuation of scopolamine-induced hyperactivity.
    O'Neill MF; Fernández AG; Gristwood RW; Palacios JM
    J Neural Transm Gen Sect; 1994; 96(1):9-18. PubMed ID: 7857593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of cholinergic and glutamatergic neuronal systems in the functional activation of cerebral blood flow response: a PET study in unanesthetized monkeys.
    Tsukada H; Kakiuchi T; Shizuno H; Nishiyama S
    Brain Res; 1998 Jun; 796(1-2):82-90. PubMed ID: 9689457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal effect of DM-9384 on scopolamine-induced acetylcholine depletion in certain regions of the mouse brain.
    Abe E
    Psychopharmacology (Berl); 1991; 105(3):310-6. PubMed ID: 1798828
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.